Similarly, in vivo TGFβ’s activation of Smad2/3 inhibited ABCG2, a chemotherapy efflux transporter, leading to reduction of gastric CSCs and overall reduction in tumor size (Ehata et al., 2011). The gene discussed is TGFB1; the disease is neoplasm.